Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 3/20 | 0.49 |
| ▸ | EDNRB | P24530 | 12/20 | 0.46 |
| ▸ | EDNRA | P25101 | 12/20 | 0.46 |
| ▸ | SGK1 | O00141 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.40 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029678 | 0.89 | IL2 (0.51) | IL2EDNRBEDNRAPIK3CDPIK3CG | |
| SCHEMBL5029432 | 0.88 | SGK1 (0.45) | IL2EDNRBEDNRASGK1PIK3CD | |
| SCHEMBL5033851 | 0.85 | SGK1 (0.48) | IL2EDNRBEDNRASGK1PIK3CD | |
| SCHEMBL5097294 | 0.85 | RORC (0.46) | IL2EDNRBEDNRAPIK3CDPIK3CG | |
| SCHEMBL8233270 | 0.84 | PIK3CD (0.45) | IL2EDNRBEDNRAPIK3CDPIK3CG | |
| SCHEMBL14377329 | 0.82 | PIK3CD (0.44) | IL2EDNRBEDNRAPIK3CDPIK3CG | |
| SCHEMBL5029384 | 0.81 | ALDH1A1 (0.47) | IL2EDNRBEDNRAPIK3CDPIK3CG | |
| SCHEMBL5033829 | 0.80 | EDNRB (0.46) | EDNRBEDNRASGK1PIK3C3HSPD1 | |
| SCHEMBL4762567 | 0.77 | IL2 (0.71) | IL2 | |
| SCHEMBL5029759 | 0.76 | IL2 (0.48) | IL2EDNRBEDNRAPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | claimed |
| EP-1983971-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | claimed |
| WO-2007087441-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1983971-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007087441-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | CCR1, NLRP1, NLRP3 | IL2 41/4885EDNRB 1617/4885EDNRA 1281/4885 |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, NLRP1, NLRP3 | IL2 41/4885EDNRB 1617/4885EDNRA 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.